D2E7: Phase II data; Phase III

Additional data from CAT and partner BASF Pharma's 284-patient European Phase II trial of D2E7 showed that weekly subcutaneous doses of 20, 40 or 80 mg of D2E7 gave a sustained reduction in the signs ...